Journal article
CD8 PET imaging with [ 89 Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Journal for immunotherapy of cancer, Vol.14(3), e012208
03/27/2026
DOI: 10.1136/jitc-2025-012208
PMCID: PMC13034240
PMID: 41895717
Abstract
CD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [
Zr]Zr-berdoxam-crefmirlimab enables whole body CD8 cell assessment and has been shown to be safe in Phase I evaluation. The correlation between CD8 PET imaging parameters and the quantity of CD8 cells assessed by the gold standard of immunohistochemistry (IHC) is unknown.
The Phase II, prospective multicenter study (iCorrelate) tested the correlation between CD8 PET and CD8 cells by IHC of core needle biopsies from patients with solid tumors receiving immune checkpoint blockade. The safety of repeat CD8 PET was additionally analyzed.
49 patients had 70 biopsies (37 baseline and 33 on-treatment) for correlating CD8 PET with IHC. Standard uptake value mean of the biopsied tumor normalized to aorta showed a correlation with IHC of 0.49 (95% CI 0.26 to 0.59). The correlation was 0.71 (95% CI 0.48 to 0.85) in patients with renal cell carcinoma. Repeat CD8 PET imaging on-treatment was safe.
We found a modest correlation between CD8 PET with [
Zr]Zr-berdoxam-crefmirlimab and intratumoral CD8 cell counts, likely because core needle biopsies do not fully represent the intratumoral heterogeneity of the CD8 cell distribution. Continued research is essential to evaluate in vivo CD8 PET signals, autoradiography, and CD8 T-cell presence by IHC in fully resected tumors. Further studies investigating the correlation between CD8 PET and immunotherapy outcomes are necessary to determine whether CD8 PET imaging could become a valuable tool for guiding immunotherapy development and informing clinical decision-making.
Details
- Title: Subtitle
- CD8 PET imaging with [ 89 Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
- Creators
- Michael A Postow - Memorial Sloan Kettering Cancer CenterPeter D Zang - City Of Hope National Medical CenterSumanta K Pal - City Of Hope National Medical CenterAudrey Mauguen - Memorial Sloan Kettering Cancer CenterMichael Farwell - Hospital of the University of PennsylvaniaMichael Gordon - HonorHealthDavid Hays - Central Arkansas Radiation Therapy InstituteJeffrey Y C Wong - City Of Hope National Medical CenterDelphine Chen - University of WashingtonGary A Ulaner - University of Southern CaliforniaGiuseppe Esposito - Georgetown UniversityJonathan McConathy - University of Alabama at BirminghamMichael M Graham - University of IowaAnthony F Shields - The Barbara Ann Karmanos Cancer InstituteAnnick D Van den Abbeele - Dana-Farber Cancer InstituteMarcus O Butler - Princess Margaret Cancer CentreJacob S Thomas - USC Norris Comprehensive Cancer CenterPrzemyslaw Twardowski - Saint John's Health CenterJayant Narang - Takeda (United States)Aman P Singh - Massachusetts Medical SocietyAgnish Dey - Massachusetts Medical SocietyKevin P Maresca - Pfizer (United States)Edmund Keliher - Pfizer (United States)Feng Liu - Pfizer (United States)Guillaume Potdevin - AstraZeneca (United States)Guenter Schmidt - AstraZeneca (United States)William Le - ImaginAb (United States)Ian Wilson - ImaginAb (United States)Alessandro Mascioni - ImaginAb (United States)Fang Jia - ImaginAb (United States)Ronald Korn - VitalantMichael R Ferris - ImaginAb (United States)Kristin Schmiedehausen - ImaginAb (United States)Neeta Pandit-Taskar - Memorial Sloan Kettering Cancer CenterKim A Margolin - City Of Hope National Medical Center
- Resource Type
- Journal article
- Publication Details
- Journal for immunotherapy of cancer, Vol.14(3), e012208
- DOI
- 10.1136/jitc-2025-012208
- PMID
- 41895717
- PMCID
- PMC13034240
- NLM abbreviation
- J Immunother Cancer
- ISSN
- 2051-1426
- eISSN
- 2051-1426
- Publisher
- BMJ Publishing Group
- Grant note
- ImaginAb Inc: N/A Takeda: N/A Pfizer: N/A AstraZeneca: N/A NIH/NCI Cancer Center: P30 CA008748
This research was supported by ImaginAb Inc and the CD8 Consortium, a joint collaboration with Pfizer, AstraZeneca, and Takeda. The study sponsor, ImaginAb Inc, was collaboratively involved in the study design with the lead and senior authors, and ImaginAb Inc was involved in the collection, analysis and interpretation of the data, in the writing of the report; and in the decision to submit the paper for publication. MAP, NPT and AM would like to acknowledge support from the NIH/NCI Cancer Center Support Grant P30 CA008748.
- Language
- English
- Date published
- 03/27/2026
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9985149627102771
Metrics
2 Record Views